Mechanism of action
Lamotrigine stabilizes neuronal membranes by blocking voltage-gated sodium channels in their inactive state, thereby inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate. This voltage-dependent blockade prevents the repetitive firing of action potentials that characterize epileptic seizures.
The drug binds preferentially to sodium channels when neurons are in a depolarized state, making it more selective for hyperexcitable tissue. This mechanism underlies both its anticonvulsant and mood-stabilizing properties. Unlike many other mood stabilizers, lamotrigine does not significantly affect GABAergic neurotransmission.
Additional proposed mechanisms include modulation of calcium channels and effects on serotonin receptors (5-HT3), though these are considered secondary to its primary sodium channel blockade.
- Stevens-Johnson syndrome risk is increased with rapid titration, valproate co-administration, or exceeding recommended initial doses
- Valproate doubles lamotrigine half-life by inhibiting glucuronidation; requires 50% dose reduction and slower titration
- Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital) halve lamotrigine half-life; higher doses needed
- Oral contraceptives reduce lamotrigine levels by 50%; bidirectional interaction affects both drug efficacies
- More effective for preventing depressive than manic episodes in bipolar disorder maintenance
- Metabolized by glucuronidation (UGT1A4), not cytochrome P450, unlike many anticonvulsants
- Discontinue immediately if rash develops with fever, lymphadenopathy, or mucous membrane involvement
- Lamotrigine clearance increases during pregnancy; therapeutic drug monitoring recommended
Indications
Epilepsy
- Focal (partial) seizures with or without secondary generalization
- Primary generalized tonic-clonic seizures
- Seizures associated with Lennox-Gastaut syndrome (pediatric and adult)
- Absence seizures in some generalized epilepsy syndromes
Lamotrigine is approved as both monotherapy and adjunctive therapy for epilepsy in adults and children (≥2 years for most indications).
Bipolar disorder
- Maintenance treatment to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients with bipolar I disorder
- Particularly effective for preventing depressive episodes in bipolar disorder
Off-label uses
- Neuropathic pain syndromes
- Borderline personality disorder
- Treatment-resistant unipolar depression (adjunctive)
Lamotrigine is notably less effective for acute mania and is not a first-line agent for acute mood episodes.
Pharmacokinetics
Absorption: Rapidly and completely absorbed after oral administration with approximately 98% bioavailability. Peak plasma concentrations occur 1.4 to 4.8 hours after dosing. Food does not significantly affect absorption.
Distribution: Volume of distribution is 0.9 to 1.3 L/kg. Approximately 55% protein bound, primarily to albumin. The drug crosses the blood-brain barrier and the placenta.
Metabolism: Hepatic metabolism via glucuronidation (UGT1A4 is the primary enzyme) to inactive metabolites. Unlike many anticonvulsants, lamotrigine does not undergo significant cytochrome P450 metabolism, reducing the potential for some drug interactions.
Elimination: Renal excretion of metabolites. The elimination half-life is approximately 24-35 hours in adults on monotherapy but is significantly affected by enzyme inducers and inhibitors:
| Concurrent medication | Approximate half-life |
|---|---|
| Monotherapy | 24-35 hours |
| With valproate | 48-70 hours (doubled) |
| With enzyme inducers* | 12-15 hours (halved) |
*Enzyme inducers include carbamazepine, phenytoin, phenobarbital, primidone, rifampin, and estrogen-containing oral contraceptives.
These pharmacokinetic interactions necessitate careful dose adjustments when starting, stopping, or changing doses of interacting medications.
Adverse effects
Dermatologic (most serious)
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Incidence approximately 0.3% in adults and 1% in children. Risk is highest in the first 8 weeks of therapy and with rapid dose escalation, concurrent valproate use, or doses exceeding recommended titration schedules.
- Benign rash occurs in 5-10% of patients, typically maculopapular and non-serious, but distinguishing from early SJS can be challenging
Neurologic
- Dizziness, ataxia, and diplopia (dose-related)
- Headache
- Somnolence or insomnia
- Tremor
- Aseptic meningitis (rare)
Psychiatric
- May precipitate mania or hypomania, particularly when used as monotherapy in bipolar disorder
- Suicidal ideation (FDA black box warning applies to all antiepileptic drugs)
Hematologic
- Blood dyscrasias including aplastic anemia, agranulocytosis (rare)
- Hemophagocytic lymphohistiocytosis (very rare but potentially fatal)
Other
- Nausea, vomiting, diarrhea
- Blurred vision
- Multi-organ hypersensitivity reactions (DRESS syndrome)
The risk of serious rash is increased with concomitant valproate therapy, exceeding recommended initial doses, or rapid dose escalation. Pediatric patients have a higher incidence of serious rash than adults.
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to lamotrigine or any component of the formulation
- History of lamotrigine-associated rash or hypersensitivity reaction
Black box warning
- Serious rashes requiring hospitalization including SJS and TEN. Risk is greater with co-administration of valproate, exceeding recommended initial doses, or rapid dose escalation. Lamotrigine should be discontinued at the first sign of rash unless the rash is clearly not drug-related.
Pregnancy and breastfeeding
- Pregnancy category C (now replaced by PLLR system). Lamotrigine is associated with increased risk of oral clefts when used in the first trimester, though the absolute risk remains relatively low.
- Pregnancy registries indicate lower teratogenic risk compared to valproate and some other anticonvulsants
- Lamotrigine levels decrease during pregnancy due to increased clearance; therapeutic drug monitoring recommended
- Excreted in breast milk; benefits vs. risks should be weighed
Renal and hepatic impairment
- Dose reduction necessary in moderate to severe hepatic impairment
- Dose adjustment may be needed in severe renal impairment
Warnings
- Aseptic meningitis has been reported; discontinue if this occurs
- Hemophagocytic lymphohistiocytosis (HLH) reported rarely
- Blood dyscrasias; monitor for signs of bone marrow suppression
- Suicidal behavior and ideation (all antiepileptic drugs carry this warning)
- Withdrawal seizures may occur with abrupt discontinuation; taper over at least 2 weeks unless safety concerns require rapid withdrawal
- May worsen myoclonic seizures in some epilepsy syndromes
Drug interactions
Valproate (valproic acid, divalproex)
- Inhibits lamotrigine glucuronidation, doubling its half-life and increasing serum concentrations
- Requires lamotrigine dose reduction (typically by 50%) and slower titration
- Significantly increases risk of serious rash
Enzyme-inducing antiepileptic drugs
- Carbamazepine, phenytoin, phenobarbital, and primidone increase lamotrigine metabolism
- Reduce lamotrigine half-life by approximately 50%
- Require higher lamotrigine doses and faster titration schedules
Estrogen-containing oral contraceptives
- Ethinyl estradiol increases lamotrigine glucuronidation, reducing lamotrigine levels by approximately 50%
- Lamotrigine may reduce contraceptive efficacy
- Starting or stopping oral contraceptives requires lamotrigine dose adjustment
- Dose may need adjustment during placebo week of oral contraceptive cycle
Other interactions
- Rifampin: Induces metabolism, reduces lamotrigine levels
- Protease inhibitors (lopinavir/ritonavir, atazanavir/ritonavir): Decrease lamotrigine levels
- Sertraline: May modestly increase lamotrigine levels
Therapeutic drug monitoring
Routine monitoring is not always necessary but may be useful when:
- Adding or removing interacting medications
- Suspecting non-adherence
- During pregnancy (increased clearance)
- In hepatic or renal impairment
- To distinguish toxicity from inadequate dosing
Target therapeutic range is not firmly established but generally considered 3-14 mcg/mL for epilepsy.
Clinical pearls
Titration is critical: The risk of serious rash is directly related to the rate of dose escalation. Slow titration per FDA-approved schedules is essential. When restarting after a gap of more than 5 half-lives, re-titration from the initial dose is recommended.
Rash management: Any rash developing during lamotrigine therapy should be evaluated promptly. Discontinue immediately if rash is accompanied by systemic symptoms (fever, lymphadenopathy, facial edema, mucous membrane involvement). The majority of rashes occur within the first 8 weeks.
Bipolar disorder efficacy: Lamotrigine is more effective at preventing depressive episodes than manic episodes in bipolar disorder. It is not effective for acute mania and should not be used as monotherapy in acute mood episodes.
Unlike lithium and valproate, lamotrigine is generally not associated with weight gain, metabolic syndrome, or cognitive dulling, making it attractive for long-term maintenance therapy.
Pregnancy considerations: Among mood stabilizers, lamotrigine has a relatively favorable reproductive safety profile compared to valproate. However, clearance increases significantly during pregnancy, often requiring dose increases with therapeutic drug monitoring.
Oral contraceptive interaction: This bidirectional interaction is clinically significant and frequently tested. Women starting or stopping oral contraceptives while on lamotrigine require dose adjustment to maintain efficacy and avoid toxicity.
Generic substitution: Lamotrigine has a narrow therapeutic index. Some clinicians recommend caution with generic substitution and monitoring for breakthrough seizures or adverse effects, though data on clinical significance are mixed.
Lennox-Gastaut syndrome: Lamotrigine is one of the few medications with demonstrated efficacy in this difficult-to-treat pediatric epilepsy syndrome, often used in combination with valproate (with appropriate dose adjustment).
Withdrawal: Unlike benzodiazepines or barbiturates, abrupt lamotrigine discontinuation does not cause a dangerous withdrawal syndrome, but seizure breakthrough can occur. Standard practice is to taper over at least 2 weeks unless a serious adverse reaction necessitates immediate discontinuation.
LAMOTRIGINE rash risk factors: L-Low and slow titration prevents rash, A-Avoid rapid escalation, M-More common with Valproate, O-Occurs in first 8 weeks, T-Titration restart needed after >5 half-lives off drug
Practice questions
1. A 28-year-old woman with bipolar I disorder has been maintained on lamotrigine 200 mg daily for the past year with good control of mood symptoms. She now presents requesting to start oral contraceptive pills for birth control. Which of the following is the most appropriate management?
2. A 19-year-old man with epilepsy develops a diffuse erythematous rash 3 weeks after starting lamotrigine. He reports the rash is mildly pruritic but denies fever, sore throat, or oral lesions. Physical examination reveals a maculopapular rash on the trunk without mucosal involvement, and vital signs are normal. Which of the following is the most appropriate next step?
3. A 45-year-old woman with focal epilepsy currently on lamotrigine 400 mg daily is started on valproate 500 mg twice daily by her neurologist for inadequate seizure control. Two weeks later she presents with severe ataxia, diplopia, and blurred vision. Her lamotrigine level is 22 mcg/mL (therapeutic range 3-14 mcg/mL). What is the mechanism of this drug interaction?
Frequently asked questions
How does lamotrigine work?
Lamotrigine blocks voltage-gated sodium channels in their inactive state, preventing repetitive neuronal firing and inhibiting the release of excitatory neurotransmitters, particularly glutamate. This mechanism stabilizes neuronal membranes and prevents both seizures and mood episodes. Unlike many other mood stabilizers, it does not primarily act through GABAergic mechanisms.
What are the side effects of lamotrigine?
The most serious side effect is Stevens-Johnson syndrome or toxic epidermal necrolysis, occurring in 0.3% of adults and 1% of children, especially with rapid titration or valproate use. Common side effects include benign rash (5-10%), dizziness, headache, diplopia, nausea, and ataxia. Rare but serious effects include aseptic meningitis, blood dyscrasias, and hemophagocytic lymphohistiocytosis. Unlike many mood stabilizers, lamotrigine typically does not cause weight gain.
Can lamotrigine be used during pregnancy?
Lamotrigine can be used during pregnancy but carries a slightly increased risk of oral clefts when used in the first trimester. Among mood stabilizers, it has a more favorable safety profile than valproate. Lamotrigine clearance increases significantly during pregnancy, often requiring dose increases with therapeutic drug monitoring to maintain seizure control or mood stability. The drug does cross into breast milk, requiring individualized risk-benefit assessment.
Lamotrigine vs valproate — what is the difference?
Lamotrigine blocks sodium channels and is primarily metabolized by glucuronidation, while valproate enhances GABA activity and inhibits multiple enzyme systems including those that metabolize lamotrigine. For bipolar disorder, lamotrigine is more effective for preventing depression, while valproate is more effective for mania. Valproate causes weight gain and is highly teratogenic, whereas lamotrigine is weight-neutral with lower teratogenic risk. When used together, valproate doubles lamotrigine levels, requiring dose reduction.
Why must lamotrigine be titrated slowly?
Slow titration is essential to minimize the risk of serious rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis. The risk of life-threatening rash is directly correlated with the rate of dose escalation and is highest when recommended titration schedules are exceeded. Rapid titration, especially with concurrent valproate use, significantly increases the incidence of these potentially fatal dermatologic reactions. The risk is greatest in the first 8 weeks of therapy.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N03AX09
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.